Drug Trial Radar · NCT07002320
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Apr 28, 2025
Primary completion
Oct 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- Institute of Cancer Research, United KingdomAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Prostate Cancer UK; Janssen Pharmaceutica N.V., Belgium; Oncology Institute of Southern Switzerland; Syntrix Biosystems, Inc.; Royal Marsden NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Belfast Health and Social Care Trust; Institute of Oncology Research (IOR)
- First posted
- Jun 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Conditions
- Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Interventions
SX-682Drug
SX-682 is supplied as 100mg film coated tablets.
ApalutamideDrug
Apalutamide is supplied as 60mg film coated tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Biologically active and tolerable dose rangeTime frame: From start of treatment to end of Cycle 2 Day 1 (each cycle is 28 days)
- Anti-tumour activity of SX-682 when administered with ApalutamideTime frame: 24 months
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland · Recruiting
Belfast Health and Social Care Trust
Belfast, United Kingdom · Recruiting
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom · Recruiting
The Royal Marsden NHS Foundation Trust - Drug Development Unit
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.